Lineage Cell Therapeutics, Inc.
LCTX
Rank in Stocks
#15259
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company,... Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Share Price
$1.08
Last synced: 2026-11-09
Market Cap
$273.14M
Change (1 day)
5.88%
Change (1 year)
-40.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lineage Cell Therapeutics, Inc. (LCTX)
Category
Healthcare
Operating Margin for Lineage Cell Therapeutics, Inc. (LCTX)
Operating Margin as of November 2026 TTM: -205.23%
According to Lineage Cell Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -205.23%. At the end of 2025 the company had an operating margin of -149.62%.
Operating Margin history for Lineage Cell Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -205.23% | 37.17% |
| 2025 | -149.62% | -33.83% |
| 2024 | -226.11% | -18.22% |
| 2023 | -276.50% | 80.52% |
| 2022 | -153.17% | -87.87% |
| 2021 | -1,263.12% | -63.08% |
| 2020 | -3,421.35% | 30.07% |
| 2019 | -2,630.31% | -10.89% |
| 2018 | -2,951.62% | 35.96% |
| 2017 | -2,170.87% | -17.09% |
| 2016 | -2,618.43% | 0.82% |
| 2015 | -2,597.04% | -0.27% |
| 2014 | -2,603.95% | 33.07% |
| 2013 | -1,956.83% | 32.50% |
| 2012 | -1,476.82% | 244.17% |
| 2011 | -429.10% | 60.29% |
| 2010 | -267.70% | 46.40% |
| 2009 | -182.86% | -2.58% |
| 2008 | -187.70% | 60.63% |
| 2007 | -116.85% | -22.49% |
| 2006 | -150.76% | -32.54% |
| 2005 | -223.47% | -21.86% |
| 2004 | -286.00% | -5.83% |
| 2003 | -303.70% | -42.23% |
| 2002 | -525.72% | -77.15% |
| 2001 | -2,300.33% | -76.28% |
| 2000 | -9,697.25% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.19% |
US
|
|
| -149.01% | -99.27% |
US
|
|
| 25.57% | -100.12% |
AU
|
|
| 31.23% | -100.15% |
BE
|
|
| 29.35% | -100.14% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lineage Cell Therapeutics, Inc.'s operating margin
What is Lineage Cell Therapeutics, Inc.'s operating margin?
Lineage Cell Therapeutics, Inc.'s operating margin is -205.23%, as of Nov 2026.
What was Lineage Cell Therapeutics, Inc.'s operating margin in 2025?
In 2025, Lineage Cell Therapeutics, Inc.'s operating margin was -149.62%, compared with -226.11% in 2024.
How has Lineage Cell Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Lineage Cell Therapeutics, Inc.'s operating margin was highest in 2025 (-149.62%) and lowest in 2020 (-3,421.35%).
How does Lineage Cell Therapeutics, Inc.'s operating margin compare with similar companies?
Lineage Cell Therapeutics, Inc.'s operating margin (-205.23%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.